Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 235

1.

Multi-arm Clinical Trials - Teams within Teams.

Langley RE, Mason MD.

Clin Oncol (R Coll Radiol). 2017 Dec;29(12):787-788. doi: 10.1016/j.clon.2017.10.001. Epub 2017 Oct 27. No abstract available.

PMID:
29111095
2.

Anticoagulated Trauma Patients: A Level I Trauma Center's Response to a Growing Geriatric Population.

Mason MD, Spilman SK, Fuchsen EA, Olson SD, Sidwell RA, Swegle JR, Sahr SM.

J Emerg Med. 2017 Oct;53(4):458-466. doi: 10.1016/j.jemermed.2017.05.023.

PMID:
29079066
3.

Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis.

Rydzewska LHM, Burdett S, Vale CL, Clarke NW, Fizazi K, Kheoh T, Mason MD, Miladinovic B, James ND, Parmar MKB, Spears MR, Sweeney CJ, Sydes MR, Tran N, Tierney JF; STOPCaP Abiraterone Collaborators.

Eur J Cancer. 2017 Oct;84:88-101. doi: 10.1016/j.ejca.2017.07.003. Epub 2017 Aug 8. Review.

4.

Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: A Systematic Review.

Lardas M, Liew M, van den Bergh RC, De Santis M, Bellmunt J, Van den Broeck T, Cornford P, Cumberbatch MG, Fossati N, Gross T, Henry AM, Bolla M, Briers E, Joniau S, Lam TB, Mason MD, Mottet N, van der Poel HG, Rouvière O, Schoots IG, Wiegel T, Willemse PM, Yuan CY, Bourke L.

Eur Urol. 2017 Dec;72(6):869-885. doi: 10.1016/j.eururo.2017.06.035. Epub 2017 Jul 27. Review.

PMID:
28757301
5.

Potential Implication of Paxillin in Cancer Establishment Within the Bone Environment.

Sobkowicz AD, Sanders AJ, Mason MD, Jiang WG.

Anticancer Res. 2017 Aug;37(8):4255-4268.

PMID:
28739717
6.

Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.

James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, Ritchie AWS, Amos CL, Gilson C, Jones RJ, Matheson D, Millman R, Attard G, Chowdhury S, Cross WR, Gillessen S, Parker CC, Russell JM, Berthold DR, Brawley C, Adab F, Aung S, Birtle AJ, Bowen J, Brock S, Chakraborti P, Ferguson C, Gale J, Gray E, Hingorani M, Hoskin PJ, Lester JF, Malik ZI, McKinna F, McPhail N, Money-Kyrle J, O'Sullivan J, Parikh O, Protheroe A, Robinson A, Srihari NN, Thomas C, Wagstaff J, Wylie J, Zarkar A, Parmar MKB, Sydes MR; STAMPEDE Investigators.

N Engl J Med. 2017 Jul 27;377(4):338-351. doi: 10.1056/NEJMoa1702900. Epub 2017 Jun 3.

PMID:
28578639
7.

Molecular Subgroup of Primary Prostate Cancer Presenting with Metastatic Biology.

Walker SM, Knight LA, McCavigan AM, Logan GE, Berge V, Sherif A, Pandha H, Warren AY, Davidson C, Uprichard A, Blayney JK, Price B, Jellema GL, Steele CJ, Svindland A, McDade SS, Eden CG, Foster C, Mills IG, Neal DE, Mason MD, Kay EW, Waugh DJ, Harkin DP, Watson RW, Clarke NW, Kennedy RD.

Eur Urol. 2017 Oct;72(4):509-518. doi: 10.1016/j.eururo.2017.03.027. Epub 2017 Apr 10.

8.

Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial.

Mason MD, Clarke NW, James ND, Dearnaley DP, Spears MR, Ritchie AWS, Attard G, Cross W, Jones RJ, Parker CC, Russell JM, Thalmann GN, Schiavone F, Cassoly E, Matheson D, Millman R, Rentsch CA, Barber J, Gilson C, Ibrahim A, Logue J, Lydon A, Nikapota AD, O'Sullivan JM, Porfiri E, Protheroe A, Srihari NN, Tsang D, Wagstaff J, Wallace J, Walmsley C, Parmar MKB, Sydes MR; STAMPEDE Investigators.

J Clin Oncol. 2017 May 10;35(14):1530-1541. doi: 10.1200/JCO.2016.69.0677. Epub 2017 Mar 13.

PMID:
28300506
9.

The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review.

Fossati N, Willemse PM, Van den Broeck T, van den Bergh RCN, Yuan CY, Briers E, Bellmunt J, Bolla M, Cornford P, De Santis M, MacPepple E, Henry AM, Mason MD, Matveev VB, van der Poel HG, van der Kwast TH, Rouvière O, Schoots IG, Wiegel T, Lam TB, Mottet N, Joniau S.

Eur Urol. 2017 Jul;72(1):84-109. doi: 10.1016/j.eururo.2016.12.003. Epub 2017 Jan 24. Review.

PMID:
28126351
10.

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.

Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, van der Poel HG, van der Kwast TH, Rouvière O, Wiegel T, Mottet N.

Eur Urol. 2017 Apr;71(4):630-642. doi: 10.1016/j.eururo.2016.08.002. Epub 2016 Aug 31.

PMID:
27591931
11.

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.

Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, Matveev VB, Moldovan PC, van den Bergh RCN, Van den Broeck T, van der Poel HG, van der Kwast TH, Rouvière O, Schoots IG, Wiegel T, Cornford P.

Eur Urol. 2017 Apr;71(4):618-629. doi: 10.1016/j.eururo.2016.08.003. Epub 2016 Aug 25.

PMID:
27568654
12.

STAMPEDE trial and patients with non-metastatic prostate cancer - Authors' reply.

James ND, Sydes MR, Clarke NW, Mason MD, Parmar MK.

Lancet. 2016 Jul 16;388(10041):235-6. doi: 10.1016/S0140-6736(16)31041-8. No abstract available.

PMID:
27479566
13.

Radiotherapy for Prostate Cancer: is it 'what you do' or 'the way that you do it'? A UK Perspective on Technique and Quality Assurance.

Mason MD, Moore R, Jones G, Lewis G, Donovan JL, Neal DE, Hamdy FC, Lane JA, Staffurth JN; ProtecT Study Group.

Clin Oncol (R Coll Radiol). 2016 Sep;28(9):e92-e100. doi: 10.1016/j.clon.2016.05.011. Epub 2016 Jul 12.

PMID:
27425582
14.

Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life.

Lane A, Metcalfe C, Young GJ, Peters TJ, Blazeby J, Avery KN, Dedman D, Down L, Mason MD, Neal DE, Hamdy FC, Donovan JL; ProtecT Study group.

BJU Int. 2016 Dec;118(6):869-879. doi: 10.1111/bju.13582. Epub 2016 Aug 17.

15.

Proteomics analysis of vesicles isolated from plasma and urine of prostate cancer patients using a multiplex, aptamer-based protein array.

Welton JL, Brennan P, Gurney M, Webber JP, Spary LK, Carton DG, Falcón-Pérez JM, Walton SP, Mason MD, Tabi Z, Clayton A.

J Extracell Vesicles. 2016 Jun 29;5:31209. doi: 10.3402/jev.v5.31209. eCollection 2016.

16.

High Risk of Neutropenia for Hormone-naive Prostate Cancer Patients Receiving STAMPEDE-style Upfront Docetaxel Chemotherapy in Usual Clinical Practice.

Tanguay JS, Catlow C, Smith C, Barber J, Staffurth J, Kumar S, Palaniappan N, Button M, Mason MD.

Clin Oncol (R Coll Radiol). 2016 Sep;28(9):611. doi: 10.1016/j.clon.2016.03.006. Epub 2016 May 4. No abstract available.

PMID:
27131755
17.
18.

Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array.

Saunders EJ, Dadaev T, Leongamornlert DA, Al Olama AA, Benlloch S, Giles GG, Wiklund F, Gronberg H, Haiman CA, Schleutker J, Nordestgaard BG, Travis RC, Neal D, Pasayan N, Khaw KT, Stanford JL, Blot WJ, Thibodeau SN, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Brenner H, Park JY, Kaneva R, Batra J, Teixeira MR, Pandha H, Govindasami K, Muir K; UK Genetic Prostate Cancer Study Collaborators; UK ProtecT Study Collaborators; PRACTICAL Consortium, Easton DF, Eeles RA, Kote-Jarai Z.

Br J Cancer. 2016 Apr 12;114(8):945-52.

19.

Prostate stromal cell proteomics analysis discriminates normal from tumour reactive stromal phenotypes.

Webber JP, Spary LK, Mason MD, Tabi Z, Brewis IA, Clayton A.

Oncotarget. 2016 Apr 12;7(15):20124-39. doi: 10.18632/oncotarget.7716.

20.

Prospective Evaluation of Sacral Neuromodulation in Children: Outcomes and Urodynamic Predictors of Success.

Mason MD, Stephany HA, Casella DP, Clayton DB, Tanaka ST, Thomas JC, Adams MC, Brock JW 3rd, Pope JC 4th.

J Urol. 2016 Apr;195(4 Pt 2):1239-44. doi: 10.1016/j.juro.2015.11.034. Epub 2016 Feb 28.

PMID:
26926536

Supplemental Content

Loading ...
Support Center